Immunovia Announces Completion of Analysis from the IMMray[™] PanCan-d Verification Study
Additional Sample Collection for Validation Study Hindered due to COVID-19 Infection Rate Increase, Causes Delay in Sales Launch LUND, SWEDEN – Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced that the Verification study analysis confirms the positive and technical performance of IMMray[™] PanCan-d, in line with previous results, further substantiating the accuracy and robustness of the IMMray[™ ]platform technology. The results showed excellent accuracy of 94% in differentiating PDAC